Neu shRNA Plasmid (h) from Santa Cruz Biotechnology, Inc. | Biocompare.com

Supplier Images

Neu shRNA Plasmid (h)

Be the first to write a review!

Citations:

Supplier Page from
Santa Cruz Biotechnology, Inc. for
Neu shRNA Plasmid (h)

Product Specs
ItemNeu shRNA Plasmid (h)
CompanySanta Cruz Biotechnology, Inc.
Price $592.00Supplier Page View Company Product Page
Catalog Numbersc-29405-SH
Quantity20 µg
RNA TypeshRNA Clones
Vector Type (Standardized)Lentiviral
NCBI Gene AliasesCD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2, p185(erbB2)
NCBI Full Gene Nameerb-b2 receptor tyrosine kinase 2
Specieshuman
TypeshRNA Plasmid

Add to Compare List

Santa Cruz Biotechnology, Inc.

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) AF8c, a Multi-Kinase Inhibitor Induces Apoptosis by Activating DR5/Nrf2 via ROS in Colorectal Cancer CellsCancersJune 21, 2022Jeong S, Farag AK, Yun HK, Jeong YA, Kim DY, Jo MJ, Park SH, Kim BR, Kim JL, Kim BG, et al.

(2) Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling PathwayMolecular cancer therapeuticsOctober 1, 2021Zhang W, Bhagwath AS, Ramzan Z, Williams TA, Subramaniyan I, Edpuganti V, Kallem RR, Dunbar KB, Ding P, Gong K, et al.

(3) Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) Promotes ATG12-Dependent Autophagy Contributing to Treatment Resistance of Breast Cancer CellsCancersMarch 2, 2021Chen Y, Wang R, Huang S, Henson ES, Bi J, Gibson SB.

(4) Erb‑B2 Receptor Tyrosine Kinase 2 is negatively regulated by the p53‑responsive microRNA‑3184‑5p in cervical cancer cellsOncology reportsJanuary 1, 2021Liu H, Li Y, Zhang J, Wu N, Liu F, Wang L, Zhang Y, Liu J, Zhang X, Guo S, et al.

(5) Targeting human epidermal growth factor receptor 2 enhances radiosensitivity and reduces the metastatic potential of Lewis lung carcinoma cellsRadiation oncology (London, England)March 6, 2020Tien Y, Tsai CL, Hou WH, Chiang Y, Hsu FM, Tsai YC, Cheng JC.

(6) Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancerBritish journal of cancerFebruary 1, 2019Li Z, Liao J, Yang Z, Choi EY, Lapidus RG, Liu X, Cullen KJ, Dan H.

(7) Algal photoprotection is regulated by the E3 ligase CUL4-DDB1^DET1Nature plantsJanuary 1, 2019Aihara Y, Fujimura-Kamada K, Yamasaki T, Minagawa J.

(8) Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung CancerMolecular cancer therapeuticsSeptember 1, 2018Shin DH, Jo JY, Han JY.

(9) A dual role of miR-22 modulated by RelA/p65 in resensitizing fulvestrant-resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382OncogenesisJuly 30, 2018Wang B, Li D, Filkowski J, Rodriguez-Juarez R, Storozynsky Q, Malach M, Carpenter E, Kovalchuk O.

(10) Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatmentCancer lettersDecember 28, 2017Shu T, Li Y, Wu X, Li B, Liu Z.

(11) MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progressionOncogeneJanuary 26, 2017Khan S, Sikander M, Ebeling MC, Ganju A, Kumari S, Yallapu MM, Hafeez BB, Ise T, Nagata S, Zafar N, et al.

(12) Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cellsCell death & diseaseJuly 21, 2016Ma S, Henson ES, Chen Y, Gibson SB.

(13) β2-AR signaling controls trastuzumab resistance-dependent pathwayOncogeneJanuary 7, 2016Liu D, Yang Z, Wang T, Yang Z, Chen H, Hu Y, Hu C, Guo L, Deng Q, Liu Y, et al.

(14) Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer CellsMolecular cancer therapeuticsMarch 1, 2015Tsai YC, Ho PY, Tzen KY, Tuan TF, Liu WL, Cheng AL, Pu YS, Cheng JC.

(15) Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cellsCancer chemotherapy and pharmacologyNovember 1, 2011Li YW, Zhu GY, Shen XL, Chu JH, Yu ZL, Fong WF.

(16) Sphingosine 1-phosphate receptor 4 uses HER2 (ERBB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cellsThe Journal of biological chemistryNovember 12, 2010Long JS, Fujiwara Y, Edwards J, Tannahill CL, Tigyi G, Pyne S, Pyne NJ.

(17) MicroRNA-21 is involved in ionizing radiation-promoted liver carcinogenesisInternational journal of clinical and experimental medicineJuly 31, 2010Zhu Y, Yu X, Fu H, Wang H, Wang P, Zheng X, Wang Y.

(18) MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancerBMC cancerMay 11, 2009Qi W, Cooke LS, Stejskal A, Riley C, Croce KD, Saldanha JW, Bearss D, Mahadevan D.

(19) tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO)BMC cancerDecember 18, 2008Menendez JA, Vazquez-Martin A, Garcia-Villalba R, Carrasco-Pancorbo A, Oliveras-Ferraros C, Fernandez-Gutierrez A, Segura-Carretero A.

(20) Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cellsMolecular cancer therapeuticsSeptember 1, 2006García-Morales P, Hernando E, Carrasco-García E, Menéndez-Gutierrez MP, Saceda M, Martínez-Lacaci I.

Be the First to Write a Review!